Sonnet BioTherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SONN and other ETFs, options, and stocks.About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. It focuses on Fully Human Albumin Binding (FHAB) technology which utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
CEORaghu Rao
CEORaghu Rao
Employees13
Employees13
HeadquartersPrinceton, New Jersey
HeadquartersPrinceton, New Jersey
Founded2011
Founded2011
Employees13
Employees13
SONN Key Statistics
Market cap29.68M
Market cap29.68M
Price-Earnings ratio-0.51
Price-Earnings ratio-0.51
Dividend yield—
Dividend yield—
Average volume773.46K
Average volume773.46K
High today$4.66
High today$4.66
Low today$4.02
Low today$4.02
Open price$4.40
Open price$4.40
Volume540.46K
Volume540.46K
52 Week high$19.30
52 Week high$19.30
52 Week low$1.08
52 Week low$1.08
Stock Snapshot
With a market cap of 29.68M, Sonnet BioTherapeutics(SONN) trades at $4.40. The stock has a price-to-earnings ratio of -0.51.
As of 2025-11-07, Sonnet BioTherapeutics(SONN) stock has fluctuated between $4.02 and $4.66. The current price stands at $4.40, placing the stock +9.5% above today's low and -5.5% off the high.
The Sonnet BioTherapeutics(SONN)'s current trading volume is 540.46K, compared to an average daily volume of 773.46K.
In the last year, Sonnet BioTherapeutics(SONN) shares hit a 52-week high of $19.30 and a 52-week low of $1.08.
In the last year, Sonnet BioTherapeutics(SONN) shares hit a 52-week high of $19.30 and a 52-week low of $1.08.
People also own
Based on the portfolios of people who own SONN. This list is generated using Robinhood data, and it’s not a recommendation.